Description
Aphobazole Pharmacodynamics
Aphobazole is a selective non-benzodiazepine anxiolytic.
Acting on sigma-1 receptors in nerve cells of the brain, Aphobazole stabilizes GABA/benzodiazepine receptors and restores their sensitivity to endogenous mediators of inhibition. Aphobazole also increases the bioenergetic potential of neurons and has a neuroprotective effect: it restores and protects nerve cells.
The action of the drug is mainly realized as a combination of anxiolytic (anti-anxiety) and mild stimulating (activating) effects. Aphobazole reduces or eliminates anxiety (anxiety, misgivings, apprehension), irritability, tension (jitteriness, tearfulness, anxiety, inability to relax, insomnia, fear), depressed mood, somatic anxiety manifestations (muscular, sensory, cardiovascular, respiratory, gastrointestinal symptoms), autonomic disturbances (dry mouth, sweating, dizziness), cognitive disturbances (difficulty concentrating, impaired memory), including those resulting from stressors. including those arising from stress disorders (adaptation disorders). The drug is especially indicated for people with predominantly asthenic personality traits such as anxious mistrustfulness, uncertainty, increased vulnerability and emotional lability, propensity to emotional stress reactions.
The effect of the drug develops on the 5th-7th day of treatment. The maximal effect is reached by the end of the 4th week of treatment and lasts for an average of 1-2 weeks after the end of the treatment period.
Aphobazole does not cause muscle weakness, drowsiness and has no negative influence on concentration and memory. Its use does not cause addiction, drug dependence and does not lead to “withdrawal” syndrome.
Indications
Aphobazole is used in adults with anxiety states: generalized anxiety disorders, neurasthenia, adaptation disorders, in patients with various somatic diseases (bronchial asthma, irritable bowel syndrome, systemic lupus erythematosus, coronary heart disease, hypertension, arrhythmias), dermatological, oncological and other diseases. In the treatment of sleep disorders associated with anxiety, neurocirculatory dystonia, premenstrual syndrome, alcohol withdrawal syndrome, to relieve withdrawal symptoms after quitting smoking.
Contraindications .
Individual intolerance to the drug. Galactose intolerance, lactase deficiency or glucose-galactose malabsorption. Pregnancy, lactation. Childhood under 18 years of age.
Administration during pregnancy and lactation
The use of the drug Aphobazole® is contraindicated when pregnant. If it is necessary to apply the drug during lactation, breastfeeding must be discontinued.
Dosage and administration
- Used orally, after a meal.
- Optimal single dose is 10 mg; daily dose is 30 mg, divided into 3 doses during the day.
- The duration of the course of application of the drug is 2-4 weeks.
- If necessary, according to the doctor’s recommendation, the daily dose of the drug may be increased to 60 mg and the duration of treatment up to 3 months.
